Liver Diseases Therapeutics Market Report 2025

The liver diseases therapeutics market size has grown strongly in recent years. It will grow from $14.16 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to high prevalence of liver diseases, alcohol consumption patterns, advancements in diagnostics, obesity and metabolic syndrome, awareness and screening programs, government initiatives for hepatitis control.

The liver diseases therapeutics market size is expected to see strong growth in the next few years. It will grow to $20.78 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to precision medicine approaches, innovations in RNA therapeutics, focus on fibrosis treatments, patient advocacy and support groups, development of vaccines for hepatitis, regulatory support for orphan drugs. Major trends in the forecast period include advancements in treatment for hepatitis c, emergence of novel therapies for liver fibrosis, exploration of immunotherapies, telemedicine and remote monitoring, focus on nutritional interventions.

The increasing prevalence of liver diseases is anticipated to drive the growth of the liver disease therapeutics market in the coming years. Liver disease encompasses any condition that affects the liver, and liver disease therapeutics provide various treatment options to address these conditions. For example, a report from the Office for Health Improvement and Disparities, a UK-based government department, indicated that in 2022, the mortality rate from liver disease for individuals under 75 in England reached 21.4 per 100,000 population. Notably, there were 6,664 premature deaths among males compared to 3,929 among females. Thus, the rising incidence of liver diseases is a significant factor propelling the growth of the liver disease therapeutics market.

The expanding geriatric population is expected to drive the growth of the low-density polyethylene (LDPE) market in the coming years. The geriatric population refers to older individuals or senior citizens who have reached or surpassed a certain age, typically associated with retirement and the later stages of life. LDPE is increasingly utilized in the pharmaceutical industry to package liver disease therapeutics, which address liver-related health issues and improve the quality of life for elderly individuals. For instance, a report from the Population Reference Bureau, a Kenya-based nonprofit organization, projected that the population of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. During the same period, this age group’s share of the overall population is expected to grow from 17% to 23%. Therefore, the expanding pharmaceutical industry, catering to the needs of the aging population, is contributing to the growth of the low-density polyethylene market.

Strategic partnerships represent a prominent trend in the liver disease therapeutics market. Leading companies within this sector are engaging in collaborations to fortify their positions. For instance, in January 2022, Aligos Therapeutics Inc., a US-based biopharmaceutical company, partnered with Merck & Co. to develop oligonucleotide therapies for non-alcoholic steatohepatitis. Similarly, in January 2021, Novartis collaborated with Alnylam to develop liver-targeted therapies as potential alternatives to transplantation for patients experiencing liver failure.

Prominent players in the liver disease therapeutics market prioritize innovative technologies, notably artificial intelligence (AI), to enhance patient care. AI applications in liver disease therapeutics involve sophisticated computational algorithms and machine learning techniques to analyze medical data, facilitating early detection, precise diagnosis, and personalized treatment strategies for liver diseases. For example, Predictive Health Intelligence, a UK-based healthcare information management company, unveiled hepatoSIGHT in February 2023. hepatoSIGHT, an AI-powered tool, predicts liver fibrosis in chronic liver disease patients, aiding case-finding and cohort mapping. It offers comprehensive data analysis, machine learning algorithms, real-time risk stratification, and user-friendly interfaces for efficient patient identification within seconds.

In September 2022, GENFIT, a biopharmaceutical company headquartered in France, completed the acquisition of Versantis for an undisclosed sum. This strategic acquisition integrates Versantis' specialized expertise in liver disease therapeutics with GENFIT's extensive knowledge in executing intricate development programs focused on liver diseases. This collaboration serves to reinforce and expedite research and development efforts, substantially broadening GENFIT's pipeline in this field. Versantis, based in Switzerland, specializes in therapeutic solutions for liver diseases.

Major companies operating in the liver diseases therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, GlaxoSmithKline PLC, Abbott Laboratories Inc., Pfizer Inc., Sanofi SA, Johnson & Johnson Services Inc., Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Limited, Valeant Pharmaceuticals, Watson Pharmaceuticals Inc., AstraZeneca PLC, Gilead Sciences Inc., Endo International PLC, Alnylam Pharmaceuticals Inc., Provectus Biopharmaceuticals Inc., Intercept Pharmaceuticals Inc., Conatus Pharmaceuticals Inc., CymaBay Therapeutics Inc., Viking Therapeutics Inc., Madrigal Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Enanta Pharmaceuticals Inc.

North America was the largest region in the liver diseases therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liver diseases therapeutics market report during the forecast period. The regions covered in the liver diseases therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liver disease therapeutics involve the treatment of various liver conditions, including those caused by viruses such as hepatitis A, B, and C. These therapies are crucial for improving the quality of life for individuals affected by liver diseases and for reducing the overall burden of liver disease on healthcare systems.

The primary disease classifications within liver disease therapeutics include hepatitis, non-alcoholic fatty liver disease, alcohol-induced conditions, and liver cancer. Hepatitis denotes liver inflammation caused by infectious viruses or noninfectious agents, leading to diverse health complications, some of which can be life-threatening. Treatment modalities encompass antiviral medications, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. End-users of these therapeutics span hospitals, ambulatory surgery centers, and other sectors.

The liver diseases therapeutics market research report is one of a series of new reports that provides liver diseases therapeutics market statistics, including liver diseases therapeutics industry global market size, regional shares, competitors with a liver diseases therapeutics market share, detailed liver diseases therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver diseases therapeutics industry. This liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver diseases therapeutics market includes revenues earned by entities by diagnosis such as imaging, laboratory tests, endoscopy, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.